About Transave
Transave is a company based in Monmouth Junction (United States) founded in 1997 was acquired by Insmed in December 2010. Transave has raised $13.04 million across 3 funding rounds from investors including Insmed. Transave operates in a competitive market with competitors including MannKind Corp, aTyr Pharma, ReCode Therapeutics, Impel NeuroPharma and Sirnaomics, among others.
- Headquarter Monmouth Junction, United States
- SectorsTechnologyHealthcare
- Website transaveinc.com
- Social LinkedIn
- Acquired by Insmed (Dec 2010)
- Legal Name Transave Inc
Funding Insights of Transave
Transave has successfully raised a total of $13.04M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2 million completed in September 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.04M
- Total Rounds 3
- Last Round Series A — $2M
- First Round $5.54M
(Nov 2009)
All 3 funding rounds of Transave with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2010 | $2M | Series A | – | – | – |
| Jun 2010 | $5.5M | Series A | – | – | – |
| Nov 2009 | $5.54M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Transave
Transave has secured backing from 1 investor. Prominent investors backing the company include Insmed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of small molecule inhibitors for rare lung diseases | 1999 | insmed.com | Bridgewater, United States |
Investor details for Transave
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Transave
4 dated milestones of Transave across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Transave is founded.
- Funding First funding round of $5.5M.
- Funding Latest funding round, Series A, of $2.0M.
- Exit Acquired by Insmed.
Competitors of Transave
Transave operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, aTyr Pharma, ReCode Therapeutics, Impel NeuroPharma and Sirnaomics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| atyrpharma.com | 2005 | San Diego, United States | $171.52M | 65 | Protein biologics are developed for treating rare diseases. | |
| recodetx.com | 2015 | Menlo Park, United States | $371M | – | Precision medicines for lung-related diseases are developed. | |
| impelnp.com | 2008 | Seattle, United States | $126.83M | 158 | Intranasal delivery technology for CNS diseases is developed. | |
| sirnaomics.com | 2007 | Gaithersburg, United States | $267M | 88 | RNA-based therapeutics for cancer and fibrosis are developed. | |
| alexza.com | 2000 | Mountain View, United States | $97M | 72 | Developer of products for the treatment of acute and intermittent conditions | |
| arcturusrx.com | 2013 | San Diego, United States | $1.3M | 337 | RNAi technologies are developed for treating rare orphan diseases. | |
| viaqua-t.com | 2014 | Rehovot, Israel | $12.55M | – | RNAi drug delivery technology is developed for aquaculture disease prevention. |
Detailed competitors of Transave
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Transave
10 companies that operate in the same segment as Transave (Nanotechnology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Developer of technologies for analysis of genetic variation and function | 1993 | San Diego, California, United States | USD 28 M | USD 1.44 M | 29 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Technology tools and systems for molecular scale are developed. | 1959 | Abingdon, Oxfordshire, United Kingdom | – | USD 648.1 M | – | |
Aerogel-based thermal insulation solutions are provided for energy conservation. | 2001 | United States | USD 198.35 M | USD 271.1 M | 554 | |
Nanotech-based electrode materials for supercapacitors are provided. | 2009 | Boston, Massachusetts, United States | USD 163.32 M | – | 66 | |
Instrument systems and software for single-molecule real-time sequencing are developed. | 2004 | Menlo Park, California, United States | USD 395 M | USD 160 M | 575 | |
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | – | 35 | |
Conductive nanocoatings are delivered via atomic layer deposition technology. | 2013 | Boulder, Colorado, United States | USD 202.75 M | – | – | |
RNA therapeutics for hematology and cardiovascular diseases are developed. | 1999 | London, England, United Kingdom | – | USD 559 K | 116 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Transave
Transave was founded in 1997 and raised its 1st funding round 12 years after it was founded.
Transave is headquartered in Monmouth Junction, United States. It is registered at Monmouth Junction, New Jersey, United States.
Transave is a funded company, having raised a total of $13.04M across 3 funding rounds to date. The company's 1st funding round was a Series A of $5.54M, raised on Nov 2009.
Transave was founded in 1997 in Monmouth Junction, United States, within the biotechnology sector. Inhaled pharmaceuticals are developed by the company for targeted treatment of serious lung infections. The lead product, ARIKACE (liposomal amikacin for inhalation), is being advanced for cystic fibrosis patients facing Pseudomonas infections and those due to non-tuberculous Mycobacteria. Operations focus on respiratory therapeutics, with development centered in the U.S.
Transave's top competitors include MannKind Corp, Sirnaomics and Arcturus Therapeutics.
Transave has 1 investor. Key investors include Insmed.
Transave operates through Transave Inc.
Yes. Transave was acquired by Insmed in December 2010.